Marlon Yovera-Aldana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marlon Yovera-Aldana has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
Anabell Tenorio-Quispe
Affiliation Universidad Científica del Sur, Lima, Peru
5 shared publicationsItalo Erazo-Cárdenas
Affiliation Universidad Científica del Sur, Lima, Peru
5 shared publicationsNallely V. Chapoñan-Agip
Affiliation Universidad Científica del Sur, Lima, Peru
5 shared publicationsSergio Barboza-Panaifo
Affiliation Universidad Científica del Sur, Lima, Peru
5 shared publicationsIsabel Pinedo-Torres
Universidad Peruana Cayetano Heredia, Lima, Peru
3 shared publicationsMartha Sofia Cervera-Ocaña
Affiliation Facultad de Ciencias Médicas, Universidad César Vallejo, Trujillo, Peru
3 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (11) , 224
Global Research Trends on Climate- and Environment-Related Exposures and Diabetes: A Scientometric Analysis
Aim: This study aimed to characterize the global scientific landscape, collaboration patterns, thematic structure, and temporal evolution of research on climate- and environment-related exposures, diabetes, and pancreatic endocrine and metabolic research between 2020 and 2025. Materials and Methods: A scientometric study was conducted using publications indexed in Scopus. The search was conducted on 12 September 2026 and was restricted to documents published between 2020 and 2025. A total of 1151 records were retrieved, of which 409 met the predefined eligibility criteria and were included in the final analysis. Bibliographic data were analyzed using Bibliometrix in R and VOSviewer. The analysis covered scientific output, citations, authorship, international collaboration, Bradford’s Law of Scattering, keyword co-occurrences, thematic evolution and collaboration. The reporting process followed RAMIBS techniques. Results: The complete dataset consisted of 409 documents from 166 sources, showing a 20.8% growth rate and an average of 18.6 citations for each document. The literature has been contributed to by 2258 authors, averaging 8.3 co-authors per document with an international co-authorship rate of 31.3%. Most of the literature types were articles (n = 340), while the rest were reviews (n = 53). The Bradford model indicated seven core journals with a good fit (R2 = 0.9847; p = 0.14). Keyword analysis indicates that the most dominant keyword is air pollution. Thematic evolution showed increasing emphasis on environmental health, mortality, chronic disease, and climate change. Country collaboration was strongest across North America, Europe, and East Asia. Exploratory life-cycle modeling suggested continued growth in scientific production during the study period. Conclusions: Research linking climate change with pancreatic endocrine and metabolic health expanded rapidly and developed a strongly collaborative and interdisciplinary structure. Air pollution, particulate matter, and diabetes-related outcomes remained central, while recent research broadened toward environmental health and disease burden.
- 19 November 2026
- Published by MDPI AG in Diabetology
- Vol. 7 (11) , 224
Open AccessGlobal Research Trends on Climate- and Environment-Related Exposures and Diabetes: A Scientometric Analysis
Aim: This study aimed to characterize the global scientific landscape, collaboration patterns, thematic structure, and temporal evolution of research on climate- and environment-related exposures, diabetes, and pancreatic endocrine and metabolic research between 2020 and 2025. Materials and Methods: A scientometric study was conducted using publications indexed in Scopus. The search was conducted on 12 September 2026 and was restricted to documents published between 2020 and 2025. A total of 1151 records were retrieved, of which 409 met the predefined eligibility criteria and were included in the final analysis. Bibliographic data were analyzed using Bibliometrix in R and VOSviewer. The analysis covered scientific output, citations, authorship, international collaboration, Bradford’s Law of Scattering, keyword co-occurrences, thematic evolution and collaboration. The reporting process followed RAMIBS techniques. Results: The complete dataset consisted of 409 documents from 166 sources, showing a 20.8% growth rate and an average of 18.6 citations for each document. The literature has been contributed to by 2258 authors, averaging 8.3 co-authors per document with an international co-authorship rate of 31.3%. Most of the literature types were articles (n = 340), while the rest were reviews (n = 53). The Bradford model indicated seven core journals with a good fit (R2 = 0.9847; p = 0.14). Keyword analysis indicates that the most dominant keyword is air pollution. Thematic evolution showed increasing emphasis on environmental health, mortality, chronic disease, and climate change. Country collaboration was strongest across North America, Europe, and East Asia. Exploratory life-cycle modeling suggested continued growth in scientific production during the study period. Conclusions: Research linking climate change with pancreatic endocrine and metabolic health expanded rapidly and developed a strongly collaborative and interdisciplinary structure. Air pollution, particulate matter, and diabetes-related outcomes remained central, while recent research broadened toward environmental health and disease burden.
- Open Access
- 3 September 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (10)
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader–Willi syndrome
Prader–Willi syndrome (PWS) is a neurogenetic disorder characterized by hyperphagia, severe obesity, and early-onset metabolic complications, in which durable weight loss is rarely achieved. We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]). He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise. At 18 months, total weight loss reached 58.8% (−108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications. Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events. Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.
- 3 September 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (10)
Open AccessSustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader–Willi syndrome
Prader–Willi syndrome (PWS) is a neurogenetic disorder characterized by hyperphagia, severe obesity, and early-onset metabolic complications, in which durable weight loss is rarely achieved. We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]). He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise. At 18 months, total weight loss reached 58.8% (−108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications. Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events. Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.
- Open Access
Publication Bias in Abstracts Presented at the American Diabetes Association Scientific Sessions: A Retrospective Cohort Study
Objective: To determine the publication rate of abstracts presented at the American Diabetes Association Scientific Sessions and to evaluate the association between statistical significance of study results and subsequent publication. Research Design and Methods: We conducted a retrospective cohort study of abstracts presented at the 2018 American Diabetes Association Scientific Sessions. The primary exposure was study result category (statistically significant vs. non-statistically significant findings), and the primary outcome was publication in an indexed journal within 5 years after conference presentation. Publication status was determined through PubMed/MEDLINE and Scopus searches. Adjusted relative risks (RRs) and 95% CIs were estimated using generalized linear models with Poisson distribution and robust variance. Results: Among 541 included abstracts, 321 (59.3%) were subsequently published in indexed journals. Abstracts reporting statistically significant findings had a higher publication rate than those reporting non-statistically significant findings (61.9% vs. 42.3%; p=0.002). In the adjusted analysis, abstracts with non-statistically significant findings had a lower likelihood of publication compared with those reporting statistically significant findings (adjusted RR 0.71 [95% CI 0.54–0.93]; p=0.012). Conclusions: Approximately four in ten abstracts presented at the ADA Scientific Sessions were not published within 5 years. Abstracts reporting non-statistically significant findings had a lower likelihood of subsequent publication, suggesting persistent publication bias in diabetology research. Future initiatives promoting the interpretation of effect estimates, confidence intervals and clinical relevance, rather than statistical significance alone, may help reduce selective dissemination of evidence
Open AccessPublication Bias in Abstracts Presented at the American Diabetes Association Scientific Sessions: A Retrospective Cohort Study
Objective: To determine the publication rate of abstracts presented at the American Diabetes Association Scientific Sessions and to evaluate the association between statistical significance of study results and subsequent publication. Research Design and Methods: We conducted a retrospective cohort study of abstracts presented at the 2018 American Diabetes Association Scientific Sessions. The primary exposure was study result category (statistically significant vs. non-statistically significant findings), and the primary outcome was publication in an indexed journal within 5 years after conference presentation. Publication status was determined through PubMed/MEDLINE and Scopus searches. Adjusted relative risks (RRs) and 95% CIs were estimated using generalized linear models with Poisson distribution and robust variance. Results: Among 541 included abstracts, 321 (59.3%) were subsequently published in indexed journals. Abstracts reporting statistically significant findings had a higher publication rate than those reporting non-statistically significant findings (61.9% vs. 42.3%; p=0.002). In the adjusted analysis, abstracts with non-statistically significant findings had a lower likelihood of publication compared with those reporting statistically significant findings (adjusted RR 0.71 [95% CI 0.54–0.93]; p=0.012). Conclusions: Approximately four in ten abstracts presented at the ADA Scientific Sessions were not published within 5 years. Abstracts reporting non-statistically significant findings had a lower likelihood of subsequent publication, suggesting persistent publication bias in diabetology research. Future initiatives promoting the interpretation of effect estimates, confidence intervals and clinical relevance, rather than statistical significance alone, may help reduce selective dissemination of evidence
- Open Access
- 20 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0337152
High prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru
Introduction: The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been associated to unfavorable clinical outcomes and a higher frequency of drug-resistant TB. Objective: To estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance tuberculosis (MDR-TB) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru. Methods: A cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB treated at a Peruvian hospital between 2015 and 2019. Drug susceptibility results were categorized as susceptible, monoresistant, polyresistant, or MDR-TB. Factors associated with MDR and resistance to at least one first-line drug were evaluated using Poisson regression models with robust variance. Results: The prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (28.4%) and rifampicin (26.2%). In the multivariable analysis, age 40–49 years (aPR = 2.99; 95% CI: 1.00–8.97) and age 70–85 years (aPR = 4.13; 95% CI: 1.16–14.7) and were independently associated with MDR-TB. Furthermore, a diabetes duration of at least 5 years was associated with resistance to at least one drug (aPR ≈ 2.1). Conclusion: A high prevalence of drug resistance, including MDR-TB was observed among patients with T2DM and pulmonary TB. Older age and longer duration of diabetes were associated with bacterial resistance in the adjusted analysis. These findings underscore the importance of considering diabetes-related clinical characteristics when evaluating drug resistance patterns in patients with tuberculosis.
- 20 August 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (8) , e0337152
Open AccessHigh prevalence of resistance to first-line drugs and multidrug resistance in patients with tuberculosis and type 2 diabetes mellitus at a referral hospital in Peru
Introduction: The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been associated to unfavorable clinical outcomes and a higher frequency of drug-resistant TB. Objective: To estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance tuberculosis (MDR-TB) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru. Methods: A cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB treated at a Peruvian hospital between 2015 and 2019. Drug susceptibility results were categorized as susceptible, monoresistant, polyresistant, or MDR-TB. Factors associated with MDR and resistance to at least one first-line drug were evaluated using Poisson regression models with robust variance. Results: The prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (28.4%) and rifampicin (26.2%). In the multivariable analysis, age 40–49 years (aPR = 2.99; 95% CI: 1.00–8.97) and age 70–85 years (aPR = 4.13; 95% CI: 1.16–14.7) and were independently associated with MDR-TB. Furthermore, a diabetes duration of at least 5 years was associated with resistance to at least one drug (aPR ≈ 2.1). Conclusion: A high prevalence of drug resistance, including MDR-TB was observed among patients with T2DM and pulmonary TB. Older age and longer duration of diabetes were associated with bacterial resistance in the adjusted analysis. These findings underscore the importance of considering diabetes-related clinical characteristics when evaluating drug resistance patterns in patients with tuberculosis.
- Open Access
- 20 June 2026
- Published by Colegio Medico del Peru in ACTA MEDICA PERUANA
- Vol. 43 (2) , 117-126
Comparación de fentermina, fentermina/ topiramato y liraglutida en la reducción de parámetros antropométricos en pacientes con obesidad: estudio de práctica clínica real
Objetivo: este estudio comparó los cambios antropométricos asociados a estos tratamientos en adultos con obesidad. Materiales y métodos: estudio observacional longitudinal de cohorte retrospectiva en 150 pacientes adultos con obesidad atendidos en un centro especializado en endocrinología en Lima, Perú. Los pacientes recibieron fentermina, fentermina/topiramato o liraglutida como parte de un programa estructurado de manejo de la obesidad. Se evaluaron los cambios en peso, índice de masa corporal (IMC), porcentaje de grasa corporal y circunferencia abdominal, entre el inicio y el seguimiento. El análisis estadístico incluyó pruebas no paramétricas(Kruskal-Wallis) y comparaciones pareadas mediante la prueba de Dunn con corrección de Bonferroni. Como análisis de sensibilidad, se realizaron modelos de regresión lineal múltiple y análisis de covarianza (ANCOVA) ajustados por posibles factores de confusión. Resultados: en la cohorte total, la pérdida media de peso fue de −9,1 ± 7,0 kg (−10,9 ± 6,9 %). El 80,7 % de los pacientes alcanzó una pérdida de peso ≥5%, el 52,0 % ≥10%, el 30,0% ≥15 % y el 12,0% ≥20%. La reducción de peso fue significativamente mayor en el grupo tratado con fentermina/topiramato en comparación con fentermina (p = 0,005). No se observaron diferencias estadísticamente significativas entre los otros pares de tratamiento para la mayoría de los desenlaces antropométricos. Los análisis de sensibilidad mostraron resultados consistentes con los hallazgos del análisis principal. Conclusiones: en la práctica clínica real, los tres esquemas farmacológicos se asociaron con reducciones clínicamente relevantes de peso y otros parámetros antropométricos. La combinación fentermina/topiramato mostró una mayor magnitud de pérdida de peso, mientras que las diferencias entre tratamientos fueron limitadas para otros desenlaces. Los análisis de sensibilidad respaldaron la consistencia de estos hallazgos.
- 20 June 2026
- Published by Colegio Medico del Peru in ACTA MEDICA PERUANA
- Vol. 43 (2) , 117-126
Open AccessComparación de fentermina, fentermina/ topiramato y liraglutida en la reducción de parámetros antropométricos en pacientes con obesidad: estudio de práctica clínica real
Objetivo: este estudio comparó los cambios antropométricos asociados a estos tratamientos en adultos con obesidad. Materiales y métodos: estudio observacional longitudinal de cohorte retrospectiva en 150 pacientes adultos con obesidad atendidos en un centro especializado en endocrinología en Lima, Perú. Los pacientes recibieron fentermina, fentermina/topiramato o liraglutida como parte de un programa estructurado de manejo de la obesidad. Se evaluaron los cambios en peso, índice de masa corporal (IMC), porcentaje de grasa corporal y circunferencia abdominal, entre el inicio y el seguimiento. El análisis estadístico incluyó pruebas no paramétricas(Kruskal-Wallis) y comparaciones pareadas mediante la prueba de Dunn con corrección de Bonferroni. Como análisis de sensibilidad, se realizaron modelos de regresión lineal múltiple y análisis de covarianza (ANCOVA) ajustados por posibles factores de confusión. Resultados: en la cohorte total, la pérdida media de peso fue de −9,1 ± 7,0 kg (−10,9 ± 6,9 %). El 80,7 % de los pacientes alcanzó una pérdida de peso ≥5%, el 52,0 % ≥10%, el 30,0% ≥15 % y el 12,0% ≥20%. La reducción de peso fue significativamente mayor en el grupo tratado con fentermina/topiramato en comparación con fentermina (p = 0,005). No se observaron diferencias estadísticamente significativas entre los otros pares de tratamiento para la mayoría de los desenlaces antropométricos. Los análisis de sensibilidad mostraron resultados consistentes con los hallazgos del análisis principal. Conclusiones: en la práctica clínica real, los tres esquemas farmacológicos se asociaron con reducciones clínicamente relevantes de peso y otros parámetros antropométricos. La combinación fentermina/topiramato mostró una mayor magnitud de pérdida de peso, mientras que las diferencias entre tratamientos fueron limitadas para otros desenlaces. Los análisis de sensibilidad respaldaron la consistencia de estos hallazgos.
- Open Access
- 18 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0329054
Post-COVID spirometric abnormalities in workers with intermittent high-altitude exposure: A cross-sectional study in Peru
Introduction: Persistent pulmonary sequelae after SARS-CoV-2 infection remain a concern in workers exposed to environmental and physiological stressors such as intermittent high-altitude hypoxia. Few studies include pre-pandemic spirometry or focus on this occupational group. Methods: A cross-sectional study was conducted in 400 sea-level-born workers intermittently exposed to altitudes >2500 m, all with confirmed COVID-19. Only A/B-quality spirometry from 2024 was included. Sociodemographic, clinical, and occupational variables were assessed, and adjusted prevalence ratios (aPR) were estimated using Poisson regression with robust variance. Results: Overall, 72.2% of workers showed spirometric abnormalities (40.5% mixed, 20.8% restrictive, 11.0% obstructive). Independent predictors included obesity (aPR 1.35; 95% CI 1.19–1.53), higher Charlson index (aPR 1.49; 95% CI 1.33–1.68), ≥ 5 years of inhalant exposure (aPR 1.64; 95% CI 1.43–1.89), ≥ 7 years of intermittent high-altitude exposure (aPR 1.81; 95% CI 1.60–2.05), and severe COVID-19 (aPR 1.65; 95% CI 1.41–1.91). Conclusions: Over 70% of participants showed abnormal spirometry was found in post-COVID-19 workers with intermittent high-altitude exposure. Respiratory function monitoring should be reinforced in this occupational group, especially among those with higher clinical and environmental risk factors.
- 18 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0329054
Open AccessPost-COVID spirometric abnormalities in workers with intermittent high-altitude exposure: A cross-sectional study in Peru
Introduction: Persistent pulmonary sequelae after SARS-CoV-2 infection remain a concern in workers exposed to environmental and physiological stressors such as intermittent high-altitude hypoxia. Few studies include pre-pandemic spirometry or focus on this occupational group. Methods: A cross-sectional study was conducted in 400 sea-level-born workers intermittently exposed to altitudes >2500 m, all with confirmed COVID-19. Only A/B-quality spirometry from 2024 was included. Sociodemographic, clinical, and occupational variables were assessed, and adjusted prevalence ratios (aPR) were estimated using Poisson regression with robust variance. Results: Overall, 72.2% of workers showed spirometric abnormalities (40.5% mixed, 20.8% restrictive, 11.0% obstructive). Independent predictors included obesity (aPR 1.35; 95% CI 1.19–1.53), higher Charlson index (aPR 1.49; 95% CI 1.33–1.68), ≥ 5 years of inhalant exposure (aPR 1.64; 95% CI 1.43–1.89), ≥ 7 years of intermittent high-altitude exposure (aPR 1.81; 95% CI 1.60–2.05), and severe COVID-19 (aPR 1.65; 95% CI 1.41–1.91). Conclusions: Over 70% of participants showed abnormal spirometry was found in post-COVID-19 workers with intermittent high-altitude exposure. Respiratory function monitoring should be reinforced in this occupational group, especially among those with higher clinical and environmental risk factors.
- Open Access
- 6 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0346081
Longitudinal changes in glycemic control and associated factors in patients with type 2 diabetes mellitus in a public referral hospital in Peru
Objectives: To evaluate longitudinal changes in glycemic control, measured by glycated hemoglobin (HbA1c), among patients with type 2 diabetes mellitus treated at a national hospital in Peru, and to identify factors associated with persistent poor glycemic control (HbA1c ≥ 7%). Methods: We conducted a retrospective cohort study including 741 patients aged 18–65 years with T2DM who had at least two HbA1c measurements (baseline and one-year follow-up) recorded between 2015 and 2019. Changes in the proportion of patients with HbA1c ≥ 7% were assessed using McNemar’s test, and individual baseline-to-follow-up HbA1c changes were evaluated. Factors associated with persistent poor glycemic control over time were examined using generalized estimating equation (GEE) models with binomial distribution and logit link. An exchangeable correlation structure and robust standard errors were applied. Progressive models were constructed according to the percentage of missing data, along with a complete-case sensitivity analysis. Results: The proportion of patients with HbA1c ≥ 7% decreased from 66.6% to 60.7% (absolute difference: 5.9%; 95% CI: 2.4–9.4; p < 0.001). Overall, 14.3% of patients improved (from ≥7% to 0.5%. In GEE models, the odds of HbA1c ≥ 7% were lower at follow-up (adjusted OR: 0.73; 95% CI: 0.61–0.88). Longer diabetes duration (≥10 years), insulin use, and hypertriglyceridemia were associated with higher odds of poor glycemic control, whereas reduced estimated glomerular filtration rate was associated with lower odds. Conclusions: Among patients with type 2 diabetes treated at a public hospital in Peru, a modest reduction in the proportion of poor glycemic control was observed after one year of follow-up. Although this reduction was statistically significant, most patients remained above recommended HbA1c targets. These findings underscore persistent gaps in diabetes management and highlight the need for strengthened clinical and public health strategies to improve glycemic control in routine care settings in Peru.
- 6 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0346081
Open AccessLongitudinal changes in glycemic control and associated factors in patients with type 2 diabetes mellitus in a public referral hospital in Peru
Objectives: To evaluate longitudinal changes in glycemic control, measured by glycated hemoglobin (HbA1c), among patients with type 2 diabetes mellitus treated at a national hospital in Peru, and to identify factors associated with persistent poor glycemic control (HbA1c ≥ 7%). Methods: We conducted a retrospective cohort study including 741 patients aged 18–65 years with T2DM who had at least two HbA1c measurements (baseline and one-year follow-up) recorded between 2015 and 2019. Changes in the proportion of patients with HbA1c ≥ 7% were assessed using McNemar’s test, and individual baseline-to-follow-up HbA1c changes were evaluated. Factors associated with persistent poor glycemic control over time were examined using generalized estimating equation (GEE) models with binomial distribution and logit link. An exchangeable correlation structure and robust standard errors were applied. Progressive models were constructed according to the percentage of missing data, along with a complete-case sensitivity analysis. Results: The proportion of patients with HbA1c ≥ 7% decreased from 66.6% to 60.7% (absolute difference: 5.9%; 95% CI: 2.4–9.4; p < 0.001). Overall, 14.3% of patients improved (from ≥7% to 0.5%. In GEE models, the odds of HbA1c ≥ 7% were lower at follow-up (adjusted OR: 0.73; 95% CI: 0.61–0.88). Longer diabetes duration (≥10 years), insulin use, and hypertriglyceridemia were associated with higher odds of poor glycemic control, whereas reduced estimated glomerular filtration rate was associated with lower odds. Conclusions: Among patients with type 2 diabetes treated at a public hospital in Peru, a modest reduction in the proportion of poor glycemic control was observed after one year of follow-up. Although this reduction was statistically significant, most patients remained above recommended HbA1c targets. These findings underscore persistent gaps in diabetes management and highlight the need for strengthened clinical and public health strategies to improve glycemic control in routine care settings in Peru.
- Open Access
Association between Gestational Weight Gain on Obstetric–Perinatal Outcomes Among Women With Pre-pregnancy Overweight or Obesity in a Peruvian Public Hospital
Objective: To evaluate the association between excessive gestational weight gain (GWG) and obstetric and perinatal outcomes among women with pre-pregnancy excess weight attending a public hospital in Lima, Peru. Methods: We conducted a retrospective cohort study using routinely collected institutional records from Hospital María Auxiliadora. Women with singleton pregnancies and pre-pregnancy body mass index (BMI) ≥25 kg/m² who delivered between January 2024 and August 2025 were included. Excessive versus non-excessive GWG was defined according to national guidelines. The primary outcome was a composite obstetric–perinatal outcome. Crude and adjusted relative risks (RRs) were estimated using Poisson regression with robust variance. Effect modification by pre-pregnancy BMI and maternal short stature was evaluated. Results: Of 6082 records, 3118 met the eligibility criteria; 31.0% had excessive GWG. In adjusted analyses, excessive GWG was associated with a small increase in the risk of the composite outcome (aRR = 1.05; 95% CI: 1.01–1.09), but not with overall obstetric outcomes (aRR = 1.04; 95% CI: 0.99–1.09) or overall perinatal outcomes (aRR = 0.99; 95% CI: 0.85–1.15). The association varied according to pre-pregnancy BMI, with higher relative risks observed among women with obesity (classes I–III). Conclusions: Among women with pre-pregnancy excess weight, excessive gestational weight gain was associated with a small increase in the risk of composite obstetric–perinatal outcomes but not with obstetric or perinatal outcomes analysed separately. The magnitude of the association differed across BMI categories, with stronger associations in higher obesity classes. These findings emphasise the importance of pre-pregnancy nutritional status when interpreting the potential impact of gestational weight gain on pregnancy outcomes.
Open AccessAssociation between Gestational Weight Gain on Obstetric–Perinatal Outcomes Among Women With Pre-pregnancy Overweight or Obesity in a Peruvian Public Hospital
Objective: To evaluate the association between excessive gestational weight gain (GWG) and obstetric and perinatal outcomes among women with pre-pregnancy excess weight attending a public hospital in Lima, Peru. Methods: We conducted a retrospective cohort study using routinely collected institutional records from Hospital María Auxiliadora. Women with singleton pregnancies and pre-pregnancy body mass index (BMI) ≥25 kg/m² who delivered between January 2024 and August 2025 were included. Excessive versus non-excessive GWG was defined according to national guidelines. The primary outcome was a composite obstetric–perinatal outcome. Crude and adjusted relative risks (RRs) were estimated using Poisson regression with robust variance. Effect modification by pre-pregnancy BMI and maternal short stature was evaluated. Results: Of 6082 records, 3118 met the eligibility criteria; 31.0% had excessive GWG. In adjusted analyses, excessive GWG was associated with a small increase in the risk of the composite outcome (aRR = 1.05; 95% CI: 1.01–1.09), but not with overall obstetric outcomes (aRR = 1.04; 95% CI: 0.99–1.09) or overall perinatal outcomes (aRR = 0.99; 95% CI: 0.85–1.15). The association varied according to pre-pregnancy BMI, with higher relative risks observed among women with obesity (classes I–III). Conclusions: Among women with pre-pregnancy excess weight, excessive gestational weight gain was associated with a small increase in the risk of composite obstetric–perinatal outcomes but not with obstetric or perinatal outcomes analysed separately. The magnitude of the association differed across BMI categories, with stronger associations in higher obesity classes. These findings emphasise the importance of pre-pregnancy nutritional status when interpreting the potential impact of gestational weight gain on pregnancy outcomes.
- Open Access
- 21 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0327601
External validation of the Meggitt-Wagner, Texas University, SINBAD, and Saint Elian classifications for predicting major amputation in patients with diabetes at a public hospital in Peru
Objective: To externally validate and compare the prognostic performance of four diabetic foot ulcer classifications—Meggitt-Wagner, University of Texas, SINBAD, and Saint Elian— for predicting major amputation in patients with diabetes treated at a public hospital in Peru. Materials and methods: We conducted a retrospective cohort study at María Auxiliadora Hospital, one of the few referral centers in Lima with a specialized Diabetic Foot Unit. The study period was January 2015 to December 2019. Eligible patients had a lower-limb ulcer, complete clinical data recorded within 48 hours of the index healthcare encounter (hospital admission or outpatient evaluation), and at least six months of follow-up. Patients with venous ulcers or pressure ulcers related to immobilization were excluded. The primary outcome was major amputation, defined as any procedure above the ankle. Prognostic performance of the four systems was assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, predictive values, and the Youden index Results: A total of 342 patients were included. All had type 2 diabetes mellitus, median age was 62 years (IQR 54–69), and 229 (67.0%) were male. The six-month cumulative incidence of major amputation was 11%. The AUROC values were: Saint Elian, 0.90; University of Texas (3D stage), 0.81; Meggitt-Wagner, 0.81; and SINBAD, 0.74. The most discriminative thresholds were SE ≥ 18, TU stage 3D, MW ≥ 3, and SINBAD ≥5. Patients with SE > 20 had a 32-fold higher risk of amputation compared with those with SE < 16. Conclusion: The Saint Elian and University of Texas systems showed the best prognostic accuracy, while Meggitt-Wagner and SINBAD performed moderately. These findings provide clinicians with clear cut-off points to identify high-risk patients and support early interventions in referral settings. Their effective use depends on multidisciplinary teams trained in diabetic foot management, and selecting the classification system most suited to hospital resources and patient profiles may help reduce amputation rates.
- 21 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0327601
Open AccessExternal validation of the Meggitt-Wagner, Texas University, SINBAD, and Saint Elian classifications for predicting major amputation in patients with diabetes at a public hospital in Peru
Objective: To externally validate and compare the prognostic performance of four diabetic foot ulcer classifications—Meggitt-Wagner, University of Texas, SINBAD, and Saint Elian— for predicting major amputation in patients with diabetes treated at a public hospital in Peru. Materials and methods: We conducted a retrospective cohort study at María Auxiliadora Hospital, one of the few referral centers in Lima with a specialized Diabetic Foot Unit. The study period was January 2015 to December 2019. Eligible patients had a lower-limb ulcer, complete clinical data recorded within 48 hours of the index healthcare encounter (hospital admission or outpatient evaluation), and at least six months of follow-up. Patients with venous ulcers or pressure ulcers related to immobilization were excluded. The primary outcome was major amputation, defined as any procedure above the ankle. Prognostic performance of the four systems was assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, predictive values, and the Youden index Results: A total of 342 patients were included. All had type 2 diabetes mellitus, median age was 62 years (IQR 54–69), and 229 (67.0%) were male. The six-month cumulative incidence of major amputation was 11%. The AUROC values were: Saint Elian, 0.90; University of Texas (3D stage), 0.81; Meggitt-Wagner, 0.81; and SINBAD, 0.74. The most discriminative thresholds were SE ≥ 18, TU stage 3D, MW ≥ 3, and SINBAD ≥5. Patients with SE > 20 had a 32-fold higher risk of amputation compared with those with SE < 16. Conclusion: The Saint Elian and University of Texas systems showed the best prognostic accuracy, while Meggitt-Wagner and SINBAD performed moderately. These findings provide clinicians with clear cut-off points to identify high-risk patients and support early interventions in referral settings. Their effective use depends on multidisciplinary teams trained in diabetic foot management, and selecting the classification system most suited to hospital resources and patient profiles may help reduce amputation rates.
- Open Access
High Prevalence of Resistance to First-Line Drugs and Multidrug Resistance in Patients with Tuberculosis and Type 2 Diabetes Mellitus at a Referral Hospital in Peru
Introduction: The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been linked to unfavorable clinical outcomes and a higher likelihood of developing drug-resistant TB. Objective: To estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance (MDR) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru. Methods: A cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB managed at Hospital María Auxiliadora between 2015 and 2019. Drug susceptibility results were categorized as sensitive, monoresistant, polyresistant, or MDR. Factors associated with MDR and resistance to at least one drug were evaluated using Poisson regression models with robust variance. Results: The prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (31%) and rifampicin (27%). In the multivariable analysis, age ≥70 years (PR = 4.13; 95% CI: 1.16–14.7) and age 40–49 years (PR = 2.99; 95% CI: 1.00–8.97) were independently associated with MDR-TB. Furthermore, a T2DM duration ≥5 years was significantly associated with resistance to at least one drug (adjusted PR ≈ 2.1). Conclusion: Patients with T2DM and pulmonary TB show a high prevalence of drug resistance, including MDR-TB. Older age and longer duration of diabetes are significant risk factors. These findings highlight the need for integrated TB–diabetes management strategies to strengthen early detection and control of drug-resistant TB in this vulnerable population.
Open AccessHigh Prevalence of Resistance to First-Line Drugs and Multidrug Resistance in Patients with Tuberculosis and Type 2 Diabetes Mellitus at a Referral Hospital in Peru
Introduction: The coexistence of tuberculosis (TB) and type 2 diabetes mellitus (T2DM) poses an emerging public health challenge, especially in high-TB-burden settings such as Peru. This comorbidity has been linked to unfavorable clinical outcomes and a higher likelihood of developing drug-resistant TB. Objective: To estimate the prevalence of resistance to first-line antituberculosis drugs and identify factors associated with multidrug resistance (MDR) among patients with T2DM and pulmonary TB treated at a public hospital in Lima, Peru. Methods: A cross-sectional study was conducted using secondary data from 130 adults with T2DM and microbiologically confirmed pulmonary TB managed at Hospital María Auxiliadora between 2015 and 2019. Drug susceptibility results were categorized as sensitive, monoresistant, polyresistant, or MDR. Factors associated with MDR and resistance to at least one drug were evaluated using Poisson regression models with robust variance. Results: The prevalence of resistance to at least one first-line drug was 34.6%, and the prevalence of MDR-TB was 21.5%. The most frequent resistances were to isoniazid (31%) and rifampicin (27%). In the multivariable analysis, age ≥70 years (PR = 4.13; 95% CI: 1.16–14.7) and age 40–49 years (PR = 2.99; 95% CI: 1.00–8.97) were independently associated with MDR-TB. Furthermore, a T2DM duration ≥5 years was significantly associated with resistance to at least one drug (adjusted PR ≈ 2.1). Conclusion: Patients with T2DM and pulmonary TB show a high prevalence of drug resistance, including MDR-TB. Older age and longer duration of diabetes are significant risk factors. These findings highlight the need for integrated TB–diabetes management strategies to strengthen early detection and control of drug-resistant TB in this vulnerable population.